Objective 1: Hypothalamus in Hormonal Regulation of the Pituitary Gland

• Anterior pituitary control: Small peptidergic neurons (parvocellular neurons) in hypothalamic nuclei (arcuate, periventricular, paraventricular) release hormones into the primary capillary plexus at the median eminence. These drain via the hypothalamo-hypophyseal portal vessels directly into the secondary plexus in the anterior pituitary — bypassing systemic circulation, so tiny amounts have large local effects.
• Posterior pituitary control: Large neurosecretory (magnocellular) neurons in supraoptic/paraventricular nuclei synthesize ADH and oxytocin as prohormones (with neurophysin carriers), transport them down axons, and store/release them directly from axon terminals in the posterior pituitary (no portal system needed here).

• GHRH → Gs-coupled receptor → ↑adenylyl cyclase → ↑cAMP → PKA → CREB-mediated transcription of the GH gene + Ca²⁺ influx → exocytosis of GH granules.
• Somatostatin → Gi-coupled receptor → ↓cAMP, opens K⁺ channels/closes Ca²⁺ channels → inhibits GH gene transcription and secretion.

• Long-loop: peripheral target-gland hormone (e.g., IGF-1) feeds back on hypothalamus.
• Short-loop: pituitary hormone (GH) feeds back on hypothalamus.
• Ultra-short-loop: a releasing hormone inhibits its own further release.

Objective 2 & 3: Growth Hormone (GH) — Structure, Synthesis, Secretion, Action, Regulation, Biochemical Role, and Hypo/Hypersecretion

Structure & site of synthesis

• GH (somatotropin) is a single-chain polypeptide of 191 amino acids (~22 kDa) with two intrachain disulfide bonds.
• Structurally homologous to prolactin and human placental lactogen (hCS) — all three belong to the same growth-hormone/prolactin gene family and adopt a four-helix-bundle fold.
• Synthesized and stored in somatotropes (acidophilic cells), the most abundant cell type (~50%) of the anterior pituitary.

Stimulus for secretion

• GHRH (from arcuate nucleus) — main physiological stimulator.
• Ghrelin (mainly gastric, also hypothalamic) — potent GH-releasing action, amplifies pulses.
• Deep (slow-wave) sleep — largest daily pulse, most prominent around puberty.
• Exercise, stress, hypoglycemia/fasting, high-protein meals/amino acids (e.g., arginine), and puberty/sex steroids (increase pulse amplitude).

Inhibitors of secretion

• Somatostatin (GHIH) — the principal inhibitor.
• IGF-1 — negative feedback: stimulates somatostatin and suppresses GHRH/GH gene transcription (long-loop).
• GH itself — short-loop feedback via somatostatin.
• Hyperglycemia, obesity/high free fatty acids, chronic glucocorticoid excess.

Mechanism of action / receptor / intracellular effects (this is the classic "biochemistry" part — know it well)

• The GH receptor (GHR) is not a GPCR and has no intrinsic enzymatic activity. It belongs to the class I cytokine receptor superfamily (single transmembrane-spanning glycoprotein).
• One GH molecule has two distinct receptor-binding sites, so it sequentially binds and dimerizes two GHR molecules.
• Dimerization brings together two molecules of the intracellularly-associated tyrosine kinase JAK2, which cross-phosphorylate and activate each other.
• Activated JAK2 phosphorylates tyrosine residues on the receptor tail, creating docking sites for STAT proteins (mainly STAT5, also STAT1/3).
• Phosphorylated STATs dimerize, translocate to the nucleus, and drive gene transcription — most importantly the IGF-1 gene in the liver.
• GH also activates the IRS-1/PI3K/Akt and Ras/MAPK(ERK) pathways, contributing to its metabolic and mitogenic effects.
• This is the JAK-STAT pathway — the same superfamily shared by prolactin, erythropoietin, and many cytokines/interferons (useful cross-link for pharmacology too — this is why JAK inhibitors and GH-receptor antagonists like pegvisomant are relevant drugs).

Target cells and biochemical roles — direct vs. IGF-1-mediated

• ↓ Glucose uptake and utilization by muscle and adipose tissue (antagonizes insulin) → hyperglycemic effect.
• ↑ Hepatic gluconeogenesis and glucose output.
• ↑ Lipolysis in adipose tissue → ↑ plasma free fatty acids → favors ketogenesis.
• Net metabolic effect: diabetogenic, ketogenic, hyperglycemic (GH excess worsens diabetes; hypophysectomy improves insulin sensitivity).

• ↑ Amino acid uptake and protein synthesis, ↓ protein catabolism → positive nitrogen balance.
• Stimulates chondrocyte proliferation at the epiphyseal growth plate → linear bone growth.
• Promotes growth of soft tissues, viscera, and skeletal muscle.
• Also: stimulates erythropoiesis, and causes mild Na⁺/water retention.

Hyposecretion of GH — Deficiency (relevant to your case)

• Children: Pituitary dwarfism — proportionate short stature, growth arrest, delayed bone age relative to chronological age, normal intelligence (matches your case exactly: 10-year-old, growth arrest x4 years, bone age 8 years at chronological age 10, no neuro symptoms, normal cognition).
• Causes: hypothalamic (GHRH deficiency) or pituitary (somatotrope) defect — congenital (mutations in GH1, GHRHR, PIT1/POU1F1, PROP1 genes; or damage during fetal development) or acquired (tumor, trauma, cranial irradiation, infection — postnatal).
• Adults: less overt — reduced lean mass, increased fat mass, reduced bone density, dyslipidemia.
• Diagnosis: Because GH secretion is pulsatile, a single random level is unreliable — a GH stimulation/provocative test (insulin, arginine, clonidine, glucagon, or GHRH) is used. A peak GH <5 ng/L is subnormal (as in your case: 4 ng/L). Serum IGF-1 is more stable and reflects average GH secretion — useful as a screening/confirmatory test.

Hypersecretion of GH — Excess

• Before epiphyseal fusion (children/adolescents): Gigantism — excessive linear growth, tall stature, visceromegaly.
• After epiphyseal fusion (adults): Acromegaly — bones can no longer lengthen (fused epiphyses) but grow in width/thickness → enlarged hands, feet, jaw (prognathism), coarse facial features, organomegaly; plus the direct anti-insulin effects cause insulin resistance/diabetes, hypertension, cardiomyopathy, carpal tunnel syndrome, sleep apnea.
• Usual cause: GH-secreting somatotroph pituitary adenoma.
• Biochemical basis: unchecked GH → excess IGF-1 → excess anabolic/mitogenic drive on bone and soft tissue, combined with GH's direct diabetogenic metabolic actions.
• Diagnosis: elevated IGF-1; failure of GH to suppress during an oral glucose tolerance test (normally glucose suppresses GH — autonomous adenoma secretion does not suppress).
• Treatment (for context): somatostatin analogues (octreotide), GH-receptor antagonist (pegvisomant), surgery.

Quick recap table for last-minute revision